Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).

Study Overview

• Status: Terminated
• Conditions: Methamphetamine Dependence
• Intervention / Treatment: Drug: CPP-109 vigabatrin; Drug: Matching Placebo

Detailed Description

This is a Phase II, randomized, double-blind, placebo-controlled, intent-to-treat, 2-arm, parallel design, multicenter study to evaluate vigabatrin as a treatment for methamphetamine addiction. The study will involve approximately 180 subjects (90/group) who meet DSM IV criteria for methamphetamine dependence. Subjects will be evaluated for their compliance with protocol inclusion/exclusion criteria during Screening/Baseline Phase, lasting up to 4 weeks.

At the conclusion of the Screening/Baseline Phase, subjects meeting all inclusion/exclusion criteria will be randomized to one of two treatment groups: vigabatrin or placebo. Subjects will proceed to a 12 week Treatment Phase and then undergo a 12 week follow-up period. Subjects will be scheduled for clinic visits 3 times per week for efficacy and/or safety assessments during the Screening/Baseline Phase and the 12 week Treatment Phase. Subjects will return for follow up visits at Weeks 13, 16, 20 and 24.

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Oceanside, California, United States
      • North County Clinical Research (NCCR)
    • San Diego, California, United States
      • South Bay Treatment Center
    • San Francisco, California, United States
      • Addiction Pharmacology Research Laboratory, St. Luke's Hospital
  • Missouri
    • Kansas City, Missouri, United States
      • START Research and Treatment
  • Nebraska
    • Omaha, Nebraska, United States
      • Creighton University Medical Center
  • New Mexico
    • Albuquerque, New Mexico, United States
      • Behavioral Health Research Center of the Southwest
  • Oklahoma
    • Oklahoma City, Oklahoma, United States
      • Pahl Pharmaceutical Research
  • Texas
    • Dallas, Texas, United States
      • Pillar Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Able to understand the study and provide written informed consent.

• Male or female at least 18 years of age.
• Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for methamphetamine dependence as major diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).
• Provides at least one urine specimen which is positive for methamphetamine according to a rapid screening test.
• Seeking treatment for methamphetamine dependence.
• Have normal visual fields.
• Be in generally good health based on history, physical examination and laboratory findings.
• If female of childbearing potential, use acceptable contraceptive methods

Exclusion Criteria:

• Has current dependence on any psychoactive substance other than methamphetamine, alcohol, nicotine, or cannabinoid or physiologic dependence on alcohol requiring medical detoxification.
• Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory values.
• Has history of serious cardiovascular reaction to methamphetamine.
• Has clinically significant cardiovascular impairment, abnormal ECG or uncontrolled hypertension.
• Be under court or other governmental agency (e.g. social services) mandate to obtain treatment or requiring outside urine monitoring.
• Be enrolled in an opiate substitution treatment program within 2 months of randomization.
• Has ever taken vigabatrin in the past.
• Is pregnant or lactating.
• Has clinically significant ophthalmologic disease, which would preclude safety monitoring, is undergoing treatment for ocular disease or intends to have any ocular surgery or procedure performed during the time of their participation in the trial.
• Has received a drug with known major organ toxicity, including retinotoxicity.
• Is currently participating in, or has been enrolled in another clinical trial within the last 30 days.
• Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: 1; CPP-109 vigabatrin tablets	Drug: CPP-109 vigabatrin; tablets, bid for 12 weeks; Other Names: GVG; gamma-vinyl GABA
PLACEBO_COMPARATOR: 2; Matching Placebo Tablets	Drug: Matching Placebo; tablets, bid, 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12).	Weeks 11-12

Secondary Outcome Measures

Outcome Measure	Time Frame
• Number of Methamphetamine Negative Urines During the Treatment Phase • Number of Methamphetamine Use Weeks During the Treatment Phase.	Weeks 1-12

Collaborators and Investigators

• Sponsor: Catalyst Pharmaceuticals, Inc.
• Investigators: Study Director: Charles W Gorodetzky, MD, PhD, Catalyst Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start: July 1, 2008
• Primary Completion (ACTUAL): June 1, 2009
• Study Completion (ACTUAL): November 1, 2009

Study Registration Dates

• First Submitted: August 5, 2008
• First Submitted That Met QC Criteria: August 5, 2008
• First Posted (ESTIMATE): August 8, 2008

Study Record Updates

• Last Update Posted (ACTUAL): December 9, 2020
• Last Update Submitted That Met QC Criteria: December 8, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Keywords: Addiction; Methamphetamine; Dependency; vigabatrin
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; GABA Agents; Anticonvulsants; Vigabatrin
• Other Study ID Numbers: CPP-02001